Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associ...

ver descrição completa

Detalhes bibliográficos
Autores: Alvarado Tapias, Edilmar, Pose Méndez, Elisa, Gratacós Ginès, Jordi, Clemente Sánchez, Ana, Hernández Évole, Helena, Bataller Alberola, Ramón, López Pelayo, Hugo
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2025
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/227438
Acesso em linha:https://hdl.handle.net/2445/227438
Access Level:Acceso aberto
Palavra-chave:Hepatopaties alcohòliques
Malalties del fetge
Consum d'alcohol
Alcoholic liver diseases
Liver diseases
Drinking of alcoholic beverages
id ES_2dda6f20784fc59e2db8f1d804abae6f
oai_identifier_str oai:recercat.cat:2445/227438
network_acronym_str ES
network_name_str España
repository_id_str
spelling Alcohol-associated liver disease: Natural history, management and novel targeted therapiesAlvarado Tapias, EdilmarPose Méndez, ElisaGratacós Ginès, JordiClemente Sánchez, AnaHernández Évole, HelenaBataller Alberola, RamónLópez Pelayo, HugoHepatopaties alcohòliquesMalalties del fetgeConsum d'alcoholAlcoholic liver diseasesLiver diseasesDrinking of alcoholic beveragesAlcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associated liver disease (ALD) encompasses a series of stages, from fatty liver (steatosis) to inflammation (steatohepatitis), fibrosis, and, ultimately, liver cirrhosis and its complications. The development of ALD is complex, involving both genetic and environmental factors, yet the exact mechanisms at play remain unclear. Alcohol-associated hepatitis (AH), a severe form of ALD, presents with sudden jaundice and liver failure. Currently, there are no approved targeted therapies able to interfere in the pathogenesis of ALD to stop the progression of the disease, making alcohol abstinence the most effective way to improve prognosis across all stages of ALD. For patients with advanced ALD who do not respond to medical therapy, liver transplantation is the only option that can improve prognosis. Recently, AH has become an early indication for liver transplantation in non-responders to medical treatment, showing promising results in carefully selected patients. This review provides an update on the epidemiology, natural history, pathogenesis, and current treatments for ALD. A deeper insight into novel targeted therapies investigated for AH focusing on new pathophysiologically-based agents is also discussed, including anti-inflammatory and antioxidative stress drugs, gut-liver axis modulators, and hepatocyte regenerative molecules. (Clin Mol Hepatol 2025;31(Suppl):S112-S133)Elsevier2026202620252026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion10 p.application/pdfhttps://hdl.handle.net/2445/227438Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3350/cmh.2024.0709Clinical And Molecular Hepatology, 2023, vol. 29, num. 1https://doi.org/10.3350/cmh.2024.0709cc-by-nc-nd (c) Hernandez Evole, Helena et al., 2023http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2274382026-05-29T05:05:01Z
dc.title.none.fl_str_mv Alcohol-associated liver disease: Natural history, management and novel targeted therapies
title Alcohol-associated liver disease: Natural history, management and novel targeted therapies
spellingShingle Alcohol-associated liver disease: Natural history, management and novel targeted therapies
Alvarado Tapias, Edilmar
Hepatopaties alcohòliques
Malalties del fetge
Consum d'alcohol
Alcoholic liver diseases
Liver diseases
Drinking of alcoholic beverages
title_short Alcohol-associated liver disease: Natural history, management and novel targeted therapies
title_full Alcohol-associated liver disease: Natural history, management and novel targeted therapies
title_fullStr Alcohol-associated liver disease: Natural history, management and novel targeted therapies
title_full_unstemmed Alcohol-associated liver disease: Natural history, management and novel targeted therapies
title_sort Alcohol-associated liver disease: Natural history, management and novel targeted therapies
dc.creator.none.fl_str_mv Alvarado Tapias, Edilmar
Pose Méndez, Elisa
Gratacós Ginès, Jordi
Clemente Sánchez, Ana
Hernández Évole, Helena
Bataller Alberola, Ramón
López Pelayo, Hugo
author Alvarado Tapias, Edilmar
author_facet Alvarado Tapias, Edilmar
Pose Méndez, Elisa
Gratacós Ginès, Jordi
Clemente Sánchez, Ana
Hernández Évole, Helena
Bataller Alberola, Ramón
López Pelayo, Hugo
author_role author
author2 Pose Méndez, Elisa
Gratacós Ginès, Jordi
Clemente Sánchez, Ana
Hernández Évole, Helena
Bataller Alberola, Ramón
López Pelayo, Hugo
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Hepatopaties alcohòliques
Malalties del fetge
Consum d'alcohol
Alcoholic liver diseases
Liver diseases
Drinking of alcoholic beverages
topic Hepatopaties alcohòliques
Malalties del fetge
Consum d'alcohol
Alcoholic liver diseases
Liver diseases
Drinking of alcoholic beverages
description Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associated liver disease (ALD) encompasses a series of stages, from fatty liver (steatosis) to inflammation (steatohepatitis), fibrosis, and, ultimately, liver cirrhosis and its complications. The development of ALD is complex, involving both genetic and environmental factors, yet the exact mechanisms at play remain unclear. Alcohol-associated hepatitis (AH), a severe form of ALD, presents with sudden jaundice and liver failure. Currently, there are no approved targeted therapies able to interfere in the pathogenesis of ALD to stop the progression of the disease, making alcohol abstinence the most effective way to improve prognosis across all stages of ALD. For patients with advanced ALD who do not respond to medical therapy, liver transplantation is the only option that can improve prognosis. Recently, AH has become an early indication for liver transplantation in non-responders to medical treatment, showing promising results in carefully selected patients. This review provides an update on the epidemiology, natural history, pathogenesis, and current treatments for ALD. A deeper insight into novel targeted therapies investigated for AH focusing on new pathophysiologically-based agents is also discussed, including anti-inflammatory and antioxidative stress drugs, gut-liver axis modulators, and hepatocyte regenerative molecules. (Clin Mol Hepatol 2025;31(Suppl):S112-S133)
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/227438
url https://hdl.handle.net/2445/227438
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3350/cmh.2024.0709
Clinical And Molecular Hepatology, 2023, vol. 29, num. 1
https://doi.org/10.3350/cmh.2024.0709
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Hernandez Evole, Helena et al., 2023
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Hernandez Evole, Helena et al., 2023
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 10 p.
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405358645051392
score 15,811543

Registros relacionados